SplitJul 22, 2026, 07:16 AM
Trinity Biotech Announces 1-for-30 Reverse ADS Split
AI Summary
Trinity Biotech plc announced a change in the ratio of its American depositary shares (ADSs) from 1 ADS representing 20 Class A ordinary shares to 1 ADS representing 600 Class A ordinary shares. This change will have the effect of a 1-for-30 reverse ADS split for current holders. The company aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement and attract a broader investor base. The change is expected to take effect on July 24, 2026, with fractional entitlements to new ADSs being sold and proceeds distributed.
Key Highlights
- Current ADS ratio: 1 ADS represents 20 Class A ordinary shares.
- New ADS ratio: 1 ADS will represent 600 Class A ordinary shares.
- Effectively a 1-for-30 reverse ADS split for holders.
- Aims to regain Nasdaq minimum bid price compliance ($1.00).
- Intends to facilitate investment from a broader pool of investors.
- Effective date for ADS trading price change is July 24, 2026.
- ADS holders must surrender 30 old ADSs for 1 new ADS.
- Fractional new ADSs will be aggregated, sold, and net proceeds distributed.
Price Impact
More from TRIB